Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of 6-Benzylaminopurine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 7/20 | 0.55 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.52 |
| ▸ | JAK1 known ✓ | P23458 | 1/20 | 0.52 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B known ✓ | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C known ✓ | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | CDK2 | P24941 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CDK1 | P06493 | 4/20 | 0.55 |
| ▸ | GALR3 | O60755 | 2/20 | 0.54 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 6-Benzylaminopurine SCHEMBL37357 | 0.98 | LMNA (0.62) | LMNATSHRMAPK1CDK2CYP1A2 | |
| 6-Benzylaminopurine SCHEMBL28824679 | 0.98 | LMNA (0.62) | LMNATSHRMAPK1CDK2CYP1A2 | |
| 6-Benzylaminopurine SCHEMBL29772173 | 0.98 | LMNA (0.62) | LMNATSHRMAPK1CDK2CYP1A2 | |
| 6-Benzylaminopurine SCHEMBL8378677 | 0.97 | LMNA (0.61) | LMNATSHRMAPK1CDK2CYP1A2 | |
| 6-Benzylaminopurine SCHEMBL11477799 | 0.97 | LMNA (0.61) | LMNATSHRMAPK1CDK2CYP1A2 | |
| 6-Benzylaminopurine SCHEMBL8018971 | 0.88 | CYP1A2 (0.52) | LMNATSHRMAPK1CDK2CYP1A2 | |
| 6-Benzylaminopurine SCHEMBL28846839 | 0.88 | LMNA (0.82) | LMNATSHRMAPK1CDK2CYP1A2 | |
| SCHEMBL4924627 | 0.87 | MEN1 (0.52) | LMNATSHRMAPK1CDK2CYP1A2 | |
| SCHEMBL15950904 | 0.85 | LMNA (0.47) | LMNATSHRMAPK1CDK2CYP1A2 | |
| SCHEMBL4920550 | 0.85 | AURKA (0.48) | LMNATSHRMAPK1CDK2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108431-A1 | PLANT GROWTH REGULATOR ADDITIVE | TAMINCO, NAAMLOZE VENNOOTSCHAP (BE) | 2012-05-03 | — | — | US | claimed |
| EP-2416653-A2 | PLANT GROWTH REGULATOR ADDITIVE | Taminco, Naamloze Vennootschap (BE) | 2012-02-15 | — | — | EP | claimed |
| WO-2010116259-A2 | PLANT GROWTH REGULATOR ADDITIVE | TAMINCO, NAAMLOZE VENNOOTSCHAP (BE) | 2010-10-14 | — | — | WO | claimed |
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | VDF FUTURECEUTICALS | 2007-07-12 | — | — | US | claimed |
| EP-1718754-A1 | PLANTS MODIFIED WITH MINI-CHROMOSOMES | Chromatin, Inc. (US) | 2006-11-08 | — | — | EP | claimed |
| WO-2005083096-A1 | PLANTS MODIFIED WITH MINI-CHROMOSOMES | CHROMATIN, INC. (US) | 2005-09-09 | — | — | WO | claimed |
| WO-2005020892-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| US-20250359548-A1 | METHODS OF IMPROVING STRESS TOLERANCE, GROWTH AND YIELD IN PLANTS | VALENT BIOSCIENCES LLC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12402623-B2 | Methods of improving stress tolerance, growth and yield in plants | VALENT BIOSCIENCES LLC (US) | 2025-09-02 | — | — | US | disclosed |
| US-20240057597-A1 | METHODS OF IMPROVING STRESS TOLERANCE, GROWTH AND YIELD IN PLANTS | VALENT BIOSCIENCES LLC (US) | 2024-02-22 | — | — | US | disclosed |
| US-11812745-B2 | Method of improving stress tolerance, growth and yield in plants | VALENT BIOSCIENCES LLC (US) | 2023-11-14 | — | — | US | disclosed |
| EP-4106523-A1 | METHODS OF IMPROVING STRESS TOLERANCE, GROWTH AND YIELD IN PLANTS | Valent BioSciences LLC (US) | 2022-12-28 | — | — | EP | disclosed |
| US-8729341-B2 | Plants modified with mini-chromosomes | UNIVERSITY OF CHICAGO (US) | 2014-05-20 | — | — | US | disclosed |
| US-20090208620-A1 | Alimentary Compositions and Methods For Metabolic Modulation | VDF FUTURECEUTICALS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090203638-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | VDF FUTURECEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20080060093-A1 | Plants Modified With Mini-Chromosomes | UNIVERSITY OF CHICAGO (US) | 2008-03-06 | — | — | US | disclosed |
| US-20070184067-A1 | Alimentary compositions and methods for metabolic modulation | VDF FUTURECEUTICALS | 2007-08-09 | — | — | US | disclosed |
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | VDF FUTURECEUTICALS | 2007-07-12 | — | — | US | disclosed |
| WO-2005020892-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005016268-A2 | ALIMENTARY COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | GPR119, PRKAG2, PRKAG1 | EGFR 4094/4885JAK2 1087/4885JAK1 2074/4885 |
| US-20090203638-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | GPR119, PRKAG2, GCKR | EGFR 4069/4885JAK2 1064/4885JAK1 1963/4885 |
| US-20120108431-A1 | PLANT GROWTH REGULATOR ADDITIVE | MYB, ING2, AGXT | EGFR 508/4885JAK2 3584/4885JAK1 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.